Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$10.56 USD
-0.03 (-0.28%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $10.56 0.00 (0.00%) 7:16 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.56 USD
-0.03 (-0.28%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $10.56 0.00 (0.00%) 7:16 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Zacks News
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the third quarter driven by clinical studies on its lead pipeline candidate, Zygel.
Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CenturyLink (CTL) Gears Up for Q3 Earnings: What's in Store?
by Zacks Equity Research
CenturyLink's (CTL) third-quarter performance is likely to have benefited from its focus on improving revenues while continuing deleveraging and cost-transformation initiatives.
Why Is Amicus Therapeutics (FOLD) Down 18.9% Since Last Earnings Report?
by Zacks Equity Research
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View
by Zacks Equity Research
Amicus' (FOLD) earnings meet estimates in the second quarter while revenues beat the same.
Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 0.00% and 7.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Amicus Therapeutics (FOLD) Down 9.6% Since Last Earnings Report?
by Zacks Equity Research
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1
by Zacks Equity Research
Amicus (FOLD) reports wider-than-expected loss in the first quarter of 2019. Also, sales miss estimates.
Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25.81% and -9.90%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Catalyst Pharma (CPRX) Q1 Earnings?
by Zacks Equity Research
Catalyst Pharma (CPRX) is expected to announce revenue results on its lead product, Firdapse, when it releases first-quarter 2019 earnings performance.
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics (FOLD) Up 12.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018
by Zacks Equity Research
Amicus (FOLD) reports wider-than-expected loss in 2018, while revenues exceed estimates.
What's in Store for Universal Health (UHS) Q4 Earnings?
by Zacks Equity Research
Universal Health's (UHS) earnings in the fourth quarter are likely to gain from higher admissions and patient days.
What's in Store for Teladoc's (TDOC) Q4 Earnings?
by Zacks Equity Research
Teladoc's (TDOC) Q4 earnings might suffer high expenses, partly offset by rise in revenues.
Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tenet Healthcare (THC) Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Tenet Healthcare's (THC) Q4 earnings are likely to suffer lower admissions due to divestitures.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis Inc. (ZTS) is gearing up to report fourth-quarter 2018 results. The company continues to strengthen its diverse product portfolio through lifecycle innovations, strong customer relationships, and access to new markets and technologies.
Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition
by Zacks Equity Research
Amicus (FOLD) is well placed after the United States approved its only marketed drug, Galafold, and the company added 14 new gene therapy programs to its pipeline for rare metabolic diseases.
Amicus Therapeutics (FOLD) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -14.81% and -11.63%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 6.7%
by Zacks Equity Research
Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold
by Zacks Equity Research
Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.
Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 0.00% and 12.65%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Amicus Therapeutics (FOLD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amicus Therapeutics (FOLD) stock based on the movements in the options market lately.